Contaminación Ambiental

Aspergillopepsin (ASP) from Aspergillus niger is a food-grade acid protease studied for gluten detoxification relevant to celiac disease. In vitro research (Ehren et al., PLOS ONE 2009) showed ASP markedly enhanced gluten digestion relative to pepsin, cleaving α2-gliadin at multiple sites; combined with DPP-IV, it achieved more complete clearance of immunotoxic epitopes.

AN-PEP (A. niger prolyl endoprotease) has been studied in celiac disease patients in a pilot study, demonstrating significantly reduced gluten reaching the duodenum. The National Celiac Association acknowledges preliminary data on AN-PEP as promising. However, current evidence does not support AN-PEP as a replacement for a gluten-free diet in diagnosed celiac patients.

Bifidobacterium genus strains are the most extensively studied probiotics in celiac disease. A 2025 PubMed review confirmed multiple in vitro and animal studies showing Bifidobacterium strains reduce gliadin-induced inflammatory cytokines, degrade gliadin peptides, and inhibit intestinal permeability in CeD models, with human clinical trials showing improvements in GI symptoms. The PMC 2020 systematic review concluded Bifidobacteria administration may restore gut microbiota composition and pre-digest gluten in CeD patients.

Bifidobacterium bifidum IATA-ES2 is specifically identified in in vitro studies as protecting against gliadin-induced inflammatory response and mucosal damage in celiac disease models, reducing IFN-γ and TNF-α while increasing IL-10. These findings are cited in the PMC 2020 systematic review and the 2025 PubMed review of Bifidobacteria in CeD. IATA-ES2 is among the most mechanistically characterized strains in celiac disease probiotic research.

Bifidobacterium breve BR03 and B632 were evaluated in a 2018 double-blind placebo-controlled trial in 40 celiac disease children, showing microbiota modulation correlating with TNF-α reductions and short-chain fatty acid changes. B. breve was also included in the VSL#3 blend tested in an RCT for celiac disease. The 2025 PubMed review includes B. breve among evidence-supported Bifidobacterium strains for CeD.

Bifidobacterium infantis NLS super strain was evaluated in a randomized double-blind placebo-controlled trial in active celiac disease patients (Smecuol et al., J Clin Gastroenterol 2013). It has also been studied in a registered ClinicalTrials.gov RCT (NCT03271138) specifically for persistent GI symptoms in CeD patients on GFD. In vitro data support its capacity to reduce gliadin-induced intestinal permeability and inflammatory markers.

Bifidobacterium lactis NLS-SS was studied in a 2013 double-blind RCT in active celiac disease patients. A 2025 RCT in 85 CeD patients used B. lactis CCT 7858 with L. rhamnosus for 90 days, concluding probiotics are beneficial adjunct therapy for CeD symptom relief. A 2008 study demonstrated B. lactis inhibits the toxic effects of wheat gliadin in epithelial cell cultures.

Bifidobacterium longum IATA-ES1 has demonstrated in vitro capacity to degrade gliadin-derived peptides and reduce gliadin-induced inflammatory cytokines in CeD cell models. B. longum ATCC 15707 reduces IFN-γ and TNF-α and increases IL-10 in response to gliadin peptides in vitro. B. longum was included in the VSL#3 blend evaluated in a randomized controlled trial in celiac disease.

Exocrine pancreatic insufficiency is a recognized co-morbidity in celiac disease, estimated to occur in 12% or more of non-responsive celiac patients. Pancreatic enzyme supplementation has been investigated in a randomized, double-blind, placebo-controlled crossover trial for non-responsive celiac disease (NRCD). Clinical guidelines suggest a trial of PERT for celiac patients with persistent malabsorption or weight loss despite a gluten-free diet. Evidence quality for this specific application is limited and considered low to moderate.

Calcium deficiency and reduced bone mineral density affect over 50% of newly diagnosed celiac disease patients due to malabsorption in the damaged proximal intestine and concurrent vitamin D deficiency. The ACG 2013 and UK NICE 2015 guidelines recommend calcium supplementation, especially combined with vitamin D, when GFD does not normalize bone mineral density. Calcium supplementation at ≥1,200 mg/day is specifically referenced in CeD management literature.

DHA deficiency is documented in celiac disease due to fat malabsorption. A 2026 University of Chile clinical trial (NCT07585669) specifically uses 2,000 mg DHA/day (plus 400 mg EPA) in newly diagnosed CeD patients alongside GFD to evaluate reduction of intestinal and systemic inflammation. DHA's anti-inflammatory mechanisms are directly relevant to CeD intestinal pathology.

Dipeptidyl peptidase IV (DPP-IV) from Aspergillus oryzae is an X-Pro amino-exopeptidase studied for its ability to release proline-containing dipeptides from gluten N-termini, complementing prolyl endopeptidases in reducing immunotoxic gluten fragments. It has been studied in combination with aspergillopepsin for gluten detoxification in celiac disease and is present in the majority of commercial glutenase supplements.

EPA is among the omega-3 fatty acids that are deficient in celiac disease due to fat malabsorption. A 2026 University of Chile clinical trial (NCT07585669) uses 400 mg EPA + 2,000 mg DHA/day in newly diagnosed CeD patients alongside GFD to evaluate reduction of intestinal inflammation. EPA's anti-inflammatory properties are directly relevant to the chronic intestinal inflammation characteristic of CeD.

Celiac disease is caused by an aberrant immune response to incompletely digested gluten peptides that resist normal gastrointestinal proteolysis. Exopeptidase supplementation has been specifically developed and clinically tested as a potential adjunct therapy to degrade these peptides before immune activation. A human crossover clinical trial demonstrated that the exopeptidase combination AMYNOPEP significantly improved in-vivo degradation of the immunodominant 33-mer gluten peptide, warranting further investigation in celiac patients.

Folate (folic acid) deficiency is one of the most common and persistent nutritional deficiencies in celiac disease, arising from malabsorption in the proximal small intestine, and may persist on long-term GFD. The 2013 ACG guidelines list folic acid among the first micronutrients to screen and supplement at diagnosis. A 2002 study by Hallert et al. demonstrated poor folate status persisting in coeliac patients after 10 years on GFD.

Iron deficiency anemia is the most common extra-intestinal manifestation of celiac disease, arising from malabsorption in the damaged duodenum and proximal jejunum. The ACG 2013 guidelines list iron as among the first micronutrients to screen and supplement at diagnosis. Iron deficiency usually resolves with strict GFD, but supplementation is warranted when deficiency persists.

Secondary lactose intolerance is highly prevalent in newly diagnosed celiac disease patients because intestinal villous damage reduces brush-border lactase enzyme levels. Oral lactase supplementation is recommended by CeD specialists while the gut heals on a gluten-free diet. Beth Israel Deaconess Medical Center, the National Celiac Association, and Beyond Celiac all explicitly cite oral lactase tablets as a management tool for CeD patients with concurrent lactose intolerance.

Lactobacillus genus strains have been studied in multiple clinical trials for celiac disease. The PMC 2020 systematic review concluded Lactobacilli may pre-digest gluten, reduce intestinal permeability, and modulate cytokine and antibody production in CeD. The VSL#3 blend containing multiple Lactobacillus strains was tested in an RCT for CeD microbiome effects.

Lactobacillus acidophilus was included in the VSL#3 probiotic blend evaluated in a randomized controlled trial in celiac disease patients (PMC4972910). L. acidophilus strains modulate humoral immune responses via TGF, IL-10, and IL-6 expression relevant to CeD. The PMC 2020 systematic review includes L. acidophilus among Lactobacilli with potential for gluten-induced immune response modulation in CeD.

Lactobacillus paracasei 8700:2 was evaluated in a 2021 randomized placebo-controlled trial in children with celiac disease autoimmunity (PMID 34249990) alongside L. plantarum HEAL9. L. paracasei was also included in the VSL#3 blend tested in an adult CeD RCT. Celiac.com (2017) reported trial data on L. paracasei 8700:2 for immune support and potential delay of CeD immune activation.

Lactobacillus plantarum HEAL9 was evaluated in a 2021 randomized placebo-controlled trial in children with celiac disease autoimmunity (PMID 34249990). L. plantarum was also included in the VSL#3 blend tested in an adult CeD RCT. Some L. plantarum strains have gluten-degrading protease activity. Celiac.com (2017) reported trial data on L. plantarum HEAL9 for immune support in CeD.

Lactobacillus rhamnosus CCT 7863 was used in a 2025 randomized controlled trial (PMID 40699044, 85 CeD patients) in combination with Bifidobacterium lactis, concluding probiotics are beneficial adjunct therapy for CeD providing symptom relief and quality of life improvement. L. rhamnosus strains are noted in CeD literature for gut barrier integrity enhancement properties relevant to the increased intestinal permeability in CeD.

Pancreatic exocrine insufficiency (PEI) is a recognized possible cause of persistent symptoms in celiac disease despite a gluten-free diet. A prospective, randomized, double-blind, placebo-controlled crossover trial of pancrelipase (lipase-containing preparation) in non-responsive celiac disease found no significant improvement in gastrointestinal symptom scores compared to placebo.

Magnesium deficiency is common in celiac disease and may persist even on long-term, compliant gluten-free diet because gluten-free cereal products contain lower magnesium than conventional counterparts. The 2013 ACG guidelines and a 2013 systematic review explicitly recognize magnesium deficiency as relevant in CeD and recommend a magnesium-enriched diet or supplementation for persistent deficiency.

Millet seed is naturally gluten-free and is documented as a safe, nutritionally superior alternative grain for individuals with celiac disease. PMC-indexed reviews confirm millets are non-allergenic and do not provoke the autoimmune intestinal response that characterizes celiac disease. Millet introduction into gluten-free diets is recommended for celiac patients.

Omega-3 fatty acid deficiency is documented in celiac disease due to gluten-induced fat malabsorption. A 2026 clinical trial at the University of Chile (NCT07585669) is evaluating 2,400 mg/day omega-3 PUFAs alongside GFD initiation in newly diagnosed CeD adults to reduce intestinal inflammation. The Gluten Free Society identifies omega-3 deficiency as more common in CeD than in the general population.

Prolyl endopeptidases (PEPs), especially the Aspergillus niger-derived AN-PEP, cleave proline-rich immunogenic gluten peptides that human gut proteases cannot fully digest. Multiple clinical trials have evaluated AN-PEP in celiac disease patients as an adjunct to a gluten-free diet; a 2024 double-blind RCT observed a significantly lower prevalence of severe symptoms in the AN-PEP arm.

Exogenous peptidase supplementation, specifically prolyl endopeptidases, has been directly studied as a potential therapy for celiac disease. Gliadin peptides are resistant to normal digestion, and prolyl endopeptidase (PEP) has been shown to cleave the immunodominant 33-mer gliadin peptide to non-toxic fragments in vivo. Research is at preclinical and early clinical trial stage.

Quinoa is naturally gluten-free and is formally recommended by dietetic guidelines (Academy of Nutrition and Dietetics) as a whole-grain alternative for celiac disease patients. Clinical dietetic guidelines recommend it as one of the preferred enriched gluten-free grains. Human studies in celiac patients consuming quinoa-containing cereal bars showed changes in cholesterol and triglycerides. Its complete nutritional profile (iron, fiber, protein) addresses common nutrient gaps in the gluten-free diet.

Rye contains secalin, a gluten-related protein that triggers the same autoimmune intestinal damage as wheat gliadin in individuals with celiac disease. Rye must be strictly excluded from the diet of people with celiac disease. This is a well-established, clinically confirmed relationship documented in major guidelines and the StatPearls/NCBI Bookshelf.

Saccharomyces boulardii KK1 reduced CD71 expression, cytokine production, and CeD-like histological changes in a mouse model when fed gluten digested with this yeast. S. boulardii CNCM I-745 reduced gluten immunopathology in immunized NOD/DQ8 mice via AhR pathway activation and synergizes with duodenal microbiota from CeD patients to increase tryptophan and AhR signaling, with researchers calling for clinical trials.

Selenium deficiency is documented in celiac disease patients on long-term gluten-free diet in a 2019 PMC systematic review of micronutrient deficiencies in compliant CeD patients. Whole grains are a primary dietary source of selenium, and their exclusion from the GFD reduces selenium intake. The 2023 Birmingham Gastroenterology Associates guidance identifies selenium deficiency in CeD as contributing to thyroid dysfunction and immune function impairment.

Streptococcus thermophilus was included in the VSL#3 probiotic blend tested in an RCT in celiac disease patients (PMC4972910; 450 billion CFU/day for 12 weeks). S. thermophilus produces lactase, which is directly relevant to the secondary lactose intolerance common in CeD. The PMC 2019 Nutrients review notes S. thermophilus among probiotics that modulate TGF, IL-10, and IL-6 expression relevant to CeD immune pathology.

Thiamine (vitamin B1) deficiency is documented in celiac disease patients on long-term gluten-free diet, identified in a 2019 PMC systematic review of micronutrient deficiencies in CeD patients with good GFD compliance. Whole grains, excluded in GFD, are a primary dietary source of thiamine; gluten-free cereal products are often less thiamine-fortified. Supplementation is included in clinical guidance for CeD nutritional management.

Vitamin B12 deficiency is documented in approximately 30% of celiac disease patients on strict GFD for more than 2 years, as the ileal mucosa where B12 is absorbed can be affected by CeD. The ACG 2013 and UK NICE 2015 guidelines recommend B12 screening and supplementation at CeD diagnosis. B12 deficiency in CeD contributes to anemia, neurological complications, and fatigue.

Riboflavin (vitamin B2) deficiency is documented in celiac disease patients on long-term gluten-free diet, identified in a 2019 PMC systematic review of micronutrient deficiencies in compliant CeD patients. Gluten-free cereal products are often unfortified and lower in riboflavin than their conventional counterparts. Riboflavin supplementation is included in clinical recommendations for CeD-related nutritional management.

Vitamin B6 deficiency is documented in celiac disease patients both at diagnosis and on long-term gluten-free diet, as confirmed by the 2013 ACG guidelines and a 2020 multinational review. A 2025 Scientific Reports cross-sectional study (59 newly diagnosed CeD vs. 59 controls) found significantly lower vitamin B6 levels in CeD patients. Deficiency may persist on established GFD, possibly due to lower B6 content in gluten-free cereal products.

Folate deficiency is among the most common and persistent nutritional deficiencies in celiac disease, resulting from impaired proximal intestinal absorption and possible continuation on long-term GFD. ACG 2013 guidelines recommend folate screening and supplementation at diagnosis. Multiple systematic reviews confirm folate deficiency in both newly diagnosed and treated CeD patients.

Methylfolate (5-MTHF) is the bioactive form of folate increasingly used in celiac disease supplementation because it bypasses intestinal and hepatic conversion steps, making it particularly advantageous in patients with intestinal malabsorption. Folate deficiency is guideline-endorsed as a primary nutritional concern in CeD, and 5-MTHF specifically addresses the absorption challenges inherent to CeD gut damage.

Vitamin D deficiency is among the most common micronutrient deficiencies in both newly diagnosed and treated celiac disease, arising from malabsorption of fat-soluble vitamins. The 2013 ACG guidelines and 2015 UK NICE guidelines recommend screening and supplementing vitamin D in CeD patients. Supplementation combined with calcium is specifically endorsed when GFD alone does not normalize bone mineral density.

Vitamin D3 (cholecalciferol) is the preferred supplemental form used to correct vitamin D deficiency in celiac disease, as endorsed by the ACG 2013 and UK NICE 2015 guidelines. Malabsorption of fat-soluble vitamins including D3 is a hallmark of untreated CeD. Combined D3 and calcium supplementation is specifically recommended when GFD alone fails to normalize bone mineral density.

Zinc deficiency is consistently documented in newly diagnosed celiac disease patients and may persist on long-term gluten-free diet, as confirmed by multiple systematic reviews and the ACG 2013 guidelines. A 2025 Scientific Reports study confirmed significantly lower zinc levels in 59 newly diagnosed CeD patients vs. controls. The ACG 2013 guidelines recommend zinc screening and supplementation at CeD diagnosis.